Free press releases distribution network?

More news: Health/Surgery
Agency / Source: Frost & Sullivan

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!



Transformation of Treatment Paradigm to Improve Patient Compliance with Multiple Sclerosis Therapy - New analysis from Frost & Sullivan, U.S. Multiple Sclerosis Markets, reveals that the market earned revenues of $3.24 billion in 2006 and estimates this to reach $7.31 billion in 2013
Transformation of Treatment Paradigm to Improve Patient Compliance with Multiple Sclerosis Therapy

 

PRZOOM - /newswire/ - Palo Alto, CA, United States, 2007/10/16 - New analysis from Frost & Sullivan, U.S. Multiple Sclerosis Markets, reveals that the market earned revenues of $3.24 billion in 2006 and estimates this to reach $7.31 billion in 2013.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Health/Surgery Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

The multiple sclerosis (MS) market is undergoing a revolution with the imminent introduction of innovative therapies that will change the approach toward the treatment of the disease. This market evolution has not escaped the notice of pharmaceutical and biotechnology companies across various tiers, as they engage in a race to develop inventive and effective treatment options for MS.

New analysis from Frost & Sullivan (pharmaceuticals.frost.com), U.S. Multiple Sclerosis Markets, reveals that the market earned revenues of $3.24 billion in 2006 and estimates this to reach $7.31 billion in 2013.

If you are interested in a virtual brochure, which provides manufacturers, end users, and other industry participants an overview of the latest analysis of the U.S. Multiple Sclerosis Markets, then send an email to Melina Trevino - Corporate Communications at melina.trevino[.]frost.com with the following information: your full name, company name, title, telephone number, email address, city, state, and country. We will send you the information via email upon receipt of the above information.

Big pharma, specialty pharma, niche pharma, biotechnology, and start-up companies could soon fill the vacuum created by the lack of an outstanding treatment option. The innovations will stand market participants in good stead, since healthcare providers are hoping to improve the standard of care and patient compliance.

"Conventional therapies have focused on managing the symptoms of the disease and delaying the progression," says Frost & Sullivan Research Analyst Barath Shankar S. "The side-effect profiles of these therapies have resulted in poor patient compliance and lower treatment rates."

The yawning gap between demand and supply of effective MS drugs has encouraged healthcare companies to devise newer ways of targeting and managing the progression of the disease. The pipeline for MS drugs is robust and includes drugs at various stages of development. They are expected to improve treatment rates and possibly, cure the disease.

"While traditional injection-based interferon therapies continue to remain the cornerstone of treatment, the next generation of therapies in development is dominated by vaccines and oral formulations that cater predominantly to the relapsing remitting type of MS," notes Shankar.

The market majors are working on potent combination therapies with interferons and other oral drugs. This could have a telling effect on the treatment paradigm of MS.

The unmet medical needs in primary progressive MS (PPMS) and secondary progressive MS (SPMS) segments are opening up significant market expansion opportunities for participants. Vendors are testing existing products for label expansion into other market segments, while simultaneously working on launching innovative therapies for the same purpose.

The U.S. Multiple Sclerosis Markets is part of the Pharmaceutical & Biotechnology Growth Partnership Service, which includes research service in the following markets: U.S. opioid and non-opioid pain management pharmaceuticals markets, Global CRO spending trends, and U.S. generic pharmaceuticals outlook. All research services included in subscriptions provide detailed market opportunities and industry trends evaluated following extensive interviews with market participants. Interviews with the press are available.

About Frost & Sullivan
Frost & Sullivan, the Growth Consulting Company, partners with clients to accelerate their growth. The company's Growth Partnership Services, Growth Consulting and Career Best Practices empower clients to create a growth focused culture that generates, evaluates and implements effective growth strategies. Frost & Sullivan employs over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 30 offices on six continents.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Health/Surgery Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: Frost & Sullivan

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 
 
  Your Banner Ad showing on ALL
Health/Surgery articles,
CATCH Visitors via Your Competitors Announcements!


Transformation of Treatment Paradigm to Improve Patient Compliance with Multiple Sclerosis Therapy

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
|
Contact: Melina Trevino 
210.247.2440 melina.trevino[.]frost.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frost & Sullivan securities in any jurisdiction including any other companies listed or named in this release.

Health/Surgery via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!




Read Latest Press Releases From Frost & Sullivan / Company Profile


Read Health/Surgery Most Recent Related Press Releases:

Sustainable Alternatives to Polyvinylidene Chloride-coated Films Create Growth Opportunities & Transform the Food Packaging Markets in Western Europe
RIKEN Biofunctional Synthetic Chemistry Laboratory in Japan Has Developed A Way to Engineer Glycan Complexes Clusters of Sugar Chains
The Clinicians of Longs Peak Emergency Physicians Join US Acute Care Solutions
Frost & Sullivan Recognizes BroadReach for Improving the Health and Wellbeing of Underserved Populations
Silver Spring Emergency Physicians Join US Acute Care Solutions
Stress Light Therapy Launches Crowd-Funded Campaign on Indiegogo.com
Frost & Sullivan Names Optum 2016 North America Company of the Year for Population Health Management
R-Pharm Produces Biological Drugs in Yaroslavl with GE Healthcare's FlexFactory™ Manufacturing Platform
GE to Invest €150 Million in Biopharmaceutical Manufacturing Campus in Cork, Ireland, and Establish Advanced Manufacturing Training Centre At NIBRT
Ultimate Medical Group Announces A New Regenerative Medicine Division

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
Find business coaching, life coaching, executive coaching and corporate coaching, best selling coaching books, ...



PREMIUM Members


Visit  La Bella Bakery Artisan Bakery Arizona

Visit  BizJobs.com

Visit  Triggr & Bloom







 
  ©2016 PRZOOM — Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today